Phyllanthus emblica as a prebiotic modulator of the gut-endocrine axis in polycystic ovary syndrome: a translational perspective on synbiotic therapeutics.

Abstract

Polycystic Ovary Syndrome (PCOS) is a complex endocrine-metabolic disorder characterized by insulin resistance, chronic inflammation, and hyperandrogenism, with emerging evidence implicating gut microbiome dysbiosis in its pathogenesis. This review explores the therapeutic potential of Phyllanthus emblica (Amla) as a prebiotic scaffold within synbiotic systems targeting the gut-endocrine axis. Rich in polyphenols, vitamin C, and dietary fibers, Amla functions both as a microbial substrate and a bioactive modulator, promoting beneficial microbiota, enhancing short-chain fatty acid production, and regulating metabolic and inflammatory pathways. Mechanistically, synbiotic modulation improves intestinal barrier integrity, suppresses NF-κB-mediated inflammation, enhances insulin sensitivity, and restores hormonal balance, thereby improving ovarian function. Evidence from preclinical studies and indirect clinical investigations in metabolic disorders suggests that Phyllanthus emblica exhibits multi-target efficacy in modulating metabolic, endocrine, and immune pathways relevant to PCOS. However, direct clinical evidence from PCOS-specific human studies remains limited. From a translational perspective, Amla-based synbiotic formulations, particularly when integrated with advanced delivery systems, represent promising pharmacological candidates for microbiome-informed therapeutics. Overall, this systems-level framework highlights the therapeutic potential of Amla-driven synbiotics while emphasizing the need for well-designed randomized clinical trials to establish their efficacy and safety in women with PCOS.